Fairvalue-Calculator Fairvalue-Calculator
EN DE

SWS Hemodialysis Care Co (688410) Fair Value & Analysis

Healthcare · CN · Market cap 4.6B CNY

Price¥14.19
Fair Value¥10.04
Upside-29.2%
Quality95/100
Evidence: High Range ¥7.53 – ¥12.55

Fair value as of: Jun 24, 2026

Analysis

SWS Hemodialysis Care Co (688410) currently trades at ¥14.19, while our model-based Fair Value estimate is ¥10.04 — implying the stock looks roughly 29.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

SWS Hemodialysis Care Co., Ltd. provides integrated blood purification solutions for renal failure and critically ill patients internationally. It offers blood purification consumables, chain hemodialysis center medical services, dialysis disposables, and a dialysis center intelligent management system, as well as operates chain dialysis centers. The company also offers blood purification equipment, which includes continuous blood purification equipment, hemodialysis machines, hemoperfusion machines and others. The company was founded in 2001 and is headquartered in Chongqing, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is SWS Hemodialysis Care Co (688410) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥10.04 versus a price of ¥14.19 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 688410?
Our 21-model fair value for SWS Hemodialysis Care Co is ¥10.04 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥14.19.
What is the quality score of 688410?
SWS Hemodialysis Care Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.